Compare STTK & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | LMNR |
|---|---|---|
| Founded | 2016 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 256.6M |
| IPO Year | 2020 | 2005 |
| Metric | STTK | LMNR |
|---|---|---|
| Price | $6.00 | $13.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $7.60 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 589.2K | 52.5K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $159,723,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $12.20 |
| 52 Week High | $6.27 | $18.40 |
| Indicator | STTK | LMNR |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 38.04 |
| Support Level | $1.85 | $12.69 |
| Resistance Level | N/A | $15.13 |
| Average True Range (ATR) | 0.42 | 0.42 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 89.41 | 27.20 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.